We are pleased to announce that Sven Weiler has joined our team in Schlieren, Switzerland as Vice President Medicinal Chemistry on August 1st, 2022.
“I very much look forward to becoming an integral part of Endogena Therapeutics and to extend my expertise among this passionate group of colleagues. It’s exciting to be joining a company that has just entered clinical stage and is developing novel therapies that could bring a potential cure to devastating diseases such as Retinis pigmentosa” explains Sven. Sven Weiler, PhD, brings more than 20 years’ experience in the pharmaceutical industry. He has worked on a broad variety of different target classes as well as on phenotypic screens for various indications. Previously Sven has been the Head of Chemistry for Basilea Pharmaceutica with a focus on Oncology and Antibacterials. Before that he was the Chemistry Head for the Musculoskeletal Disease Area at Novartis. Welcome to the team Sven!